Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24338556 | 0.81 | — | — | |
| SCHEMBL19852845 | 0.80 | GRIN1 (0.32) | GRIN1GRIN2AGRIN2B | |
| SCHEMBL24339026 | 0.80 | DPP4 (0.34) | GRIN2B | |
| SCHEMBL24339455 | 0.79 | — | — | |
| SCHEMBL24339016 | 0.78 | — | — | |
| SCHEMBL19852917 | 0.76 | JAK3 (0.34) | GRIN1GRIN2AGRIN2B | |
| SCHEMBL24338565 | 0.76 | DPP4 (0.36) | GRIN2B | |
| SCHEMBL19852916 | 0.76 | GRIN1 (0.34) | GRIN1GRIN2AGRIN2B | |
| SCHEMBL24338525 | 0.75 | ALOX15 (0.33) | — | |
| SCHEMBL19852891 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-10-05 | — | — | US | disclosed |
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | GRIN1 1/4885GRIN2A 2/4885GRIN2B 5/4885 |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN1 1/4885GRIN2A 2/4885GRIN2B 5/4885 |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN1 1/4885GRIN2A 2/4885GRIN2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.